Endocyte Inc (ECYT) 3.52 $ECYT
Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Thu May 26, 3:01PM CDT
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 - 7, 2016, in Chicago.
ECYT: 3.52 (+0.20)
Endocyte (ECYT) Reports Narrower than Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu May 05, 3:01PM CDT
Endocyte, Inc. (ECYT) reported a first-quarter 2016 loss of 24 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 26 cents and the year-ago loss of 26 cents.
MNK: 58.72 (+2.04), ECYT: 3.52 (+0.20), SHPG: 180.29 (+4.91), NKTR: 15.54 (+0.45)
Endocyte (ECYT) Reports a Narrower Q1 Loss
Ekta Bagri - Zacks Investment Research - Wed May 04, 7:53AM CDT
Endocyte reported a loss per share of 24 cents per share while our consensus called for a loss of 26 cents per share
ECYT: 3.52 (+0.20)
Endocyte reports 1Q loss
Automated Insights - Wed May 04, 7:22AM CDT
WEST LAFAYETTE, Ind. (AP) _ Endocyte Inc. (ECYT) on Wednesday reported a loss of $10.9 million in its first quarter.
ECYT: 3.52 (+0.20)
Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More
Zacks Equity Research - Zacks Investment Research - Tue May 03, 8:08AM CDT
How will biotech stocks Regeneron, Ligand, Ionis and others fare in the first quarter of 2016?
RDUS: 37.24 (+1.57), ECYT: 3.52 (+0.20), CLDX: 4.57 (+0.12), LGND: 115.11 (+1.28), AMGN: 152.27 (+2.46), IONS: 23.60 (+1.01), REGN: 357.14 (+5.22)
Endocyte (ECYT): What Awaits the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:20AM CDT
Endocyte, Inc. (ECYT) is slated to report first-quarter 2016 results on May 4.
IPXL: 30.33 (+0.81), ECYT: 3.52 (+0.20), JAZZ: 145.00 (+2.06), XON: 25.20 (+0.55)
Endocyte Announces First Quarter 2016 Earnings Conference Call
GlobeNewswire - Wed Apr 27, 3:01PM CDT
Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 4th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update.
ECYT: 3.52 (+0.20)
Endocyte Announces Promising Preclinical Data for Application of SMDC Technology in CAR T Cell Therapy in Late-Breaking Abstract at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:01AM CDT
-- Poster demonstrates novel approach to a universal T cell overcoming key challenges of current chimeric antigen receptor (CAR) technologies/therapies
ECYT: 3.52 (+0.20)
Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Mon Apr 11, 3:01PM CDT
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annual Meeting 2016 to be held in New Orleans, April 16-20, 2016.
ECYT: 3.52 (+0.20)
Intercept (ICPT) Up Ahead of Advisory Committee Meeting
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 10:10AM CDT
Shares of Intercept Pharmaceuticals, Inc. (ICPT) surged 13.3% just before the FDA Gastrointestinal Drug Advisory Committee's (GIDAC) meeting scheduled for Apr 7, 2016.
ECYT: 3.52 (+0.20), ARQL: 1.92 (+0.03), SCMP: 10.95 (+0.15), ICPT: 154.26 (+6.16)
Valeant Completes Accounting Review of Philidor, Shares Up
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:30AM CDT
Valeant Pharmaceuticals (VRX) announced that an accounting review related to Philidor, which was undertaken by the ad hoc committee appointed by the board of directors, has been completed witth no additional restatements required.
ECYT: 3.52 (+0.20), VRX: 22.25 (+0.61), ARQL: 1.92 (+0.03), SCMP: 10.95 (+0.15)
Endocyte (ECYT): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:45AM CDT
Endocyte (ECYT) is seeing good earnings estimate revision activity, and is well positioned from a Zacks Industry Rank perspective.
ECYT: 3.52 (+0.20)
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q4
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 8:20AM CST
Endocyte, Inc. (ECYT) reported a fourth-quarter 2015 loss of 23 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents but wider than the year-ago loss of 19 cents.
ECYT: 3.52 (+0.20), ARQL: 1.92 (+0.03), CORT: 5.47 (+0.17), CELG: 100.66 (+1.43)
Endocyte Reports Fourth Quarter and Year End 2015 Financial Results and Provides Clinical and Pipeline Update
GlobeNewswire - Wed Mar 02, 3:01PM CST
- EC1456 and EC1169 Advance in Phase 1 Dose Escalation Studies -
ECYT: 3.52 (+0.20)
What's in Store for Endocyte (ECYT) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue Mar 01, 4:19PM CST
Endocyte, Inc. (ECYT) is slated to report fourth-quarter 2015 results on Mar 2, 2016.
ECYT: 3.52 (+0.20), VRX: 22.25 (+0.61), ADRO: 10.93 (+0.70), MRNS: 1.43 (+0.09)
BUYINS.NET: SOXL, AMRC, GDOT, SCHC, ECYT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Feb 04, 6:31AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Direxion Daily Semiconductor Bull 3X Shares (NYSE:SOXL), Ameresco Inc (NYSE:AMRC), Green Dot Corp (NYSE:GDOT), Schwab US Large Cap Etf (NYSE:SCHC), ENDOCYTE INC (NASDAQ:ECYT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
AMRC: 4.97 (+0.16), ECYT: 3.52 (+0.20), GDOT: 22.40 (+0.36), SOXL: 31.52 (+2.28), SCHC: 30.47 (+0.65)
Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Thu May 26, 3:01PM CDT
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 - 7, 2016, in Chicago.
ECYT: 3.52 (+0.20)
Endocyte (ECYT) Reports Narrower than Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu May 05, 3:01PM CDT
Endocyte, Inc. (ECYT) reported a first-quarter 2016 loss of 24 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 26 cents and the year-ago loss of 26 cents.
MNK: 58.72 (+2.04), ECYT: 3.52 (+0.20), SHPG: 180.29 (+4.91), NKTR: 15.54 (+0.45)
Endocyte (ECYT) Reports a Narrower Q1 Loss
Ekta Bagri - Zacks Investment Research - Wed May 04, 7:53AM CDT
Endocyte reported a loss per share of 24 cents per share while our consensus called for a loss of 26 cents per share
ECYT: 3.52 (+0.20)
Endocyte reports 1Q loss
Automated Insights - Wed May 04, 7:22AM CDT
WEST LAFAYETTE, Ind. (AP) _ Endocyte Inc. (ECYT) on Wednesday reported a loss of $10.9 million in its first quarter.
ECYT: 3.52 (+0.20)
Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More
Zacks Equity Research - Zacks Investment Research - Tue May 03, 8:08AM CDT
How will biotech stocks Regeneron, Ligand, Ionis and others fare in the first quarter of 2016?
RDUS: 37.24 (+1.57), ECYT: 3.52 (+0.20), CLDX: 4.57 (+0.12), LGND: 115.11 (+1.28), AMGN: 152.27 (+2.46), IONS: 23.60 (+1.01), REGN: 357.14 (+5.22)
Endocyte (ECYT): What Awaits the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:20AM CDT
Endocyte, Inc. (ECYT) is slated to report first-quarter 2016 results on May 4.
IPXL: 30.33 (+0.81), ECYT: 3.52 (+0.20), JAZZ: 145.00 (+2.06), XON: 25.20 (+0.55)
Endocyte Announces First Quarter 2016 Earnings Conference Call
GlobeNewswire - Wed Apr 27, 3:01PM CDT
Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 4th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update.
ECYT: 3.52 (+0.20)
Endocyte Announces Promising Preclinical Data for Application of SMDC Technology in CAR T Cell Therapy in Late-Breaking Abstract at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:01AM CDT
-- Poster demonstrates novel approach to a universal T cell overcoming key challenges of current chimeric antigen receptor (CAR) technologies/therapies
ECYT: 3.52 (+0.20)
Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Mon Apr 11, 3:01PM CDT
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annual Meeting 2016 to be held in New Orleans, April 16-20, 2016.
ECYT: 3.52 (+0.20)
Intercept (ICPT) Up Ahead of Advisory Committee Meeting
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 10:10AM CDT
Shares of Intercept Pharmaceuticals, Inc. (ICPT) surged 13.3% just before the FDA Gastrointestinal Drug Advisory Committee's (GIDAC) meeting scheduled for Apr 7, 2016.
ECYT: 3.52 (+0.20), ARQL: 1.92 (+0.03), SCMP: 10.95 (+0.15), ICPT: 154.26 (+6.16)
Valeant Completes Accounting Review of Philidor, Shares Up
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:30AM CDT
Valeant Pharmaceuticals (VRX) announced that an accounting review related to Philidor, which was undertaken by the ad hoc committee appointed by the board of directors, has been completed witth no additional restatements required.
ECYT: 3.52 (+0.20), VRX: 22.25 (+0.61), ARQL: 1.92 (+0.03), SCMP: 10.95 (+0.15)
Endocyte (ECYT): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:45AM CDT
Endocyte (ECYT) is seeing good earnings estimate revision activity, and is well positioned from a Zacks Industry Rank perspective.
ECYT: 3.52 (+0.20)
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q4
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 8:20AM CST
Endocyte, Inc. (ECYT) reported a fourth-quarter 2015 loss of 23 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents but wider than the year-ago loss of 19 cents.
ECYT: 3.52 (+0.20), ARQL: 1.92 (+0.03), CORT: 5.47 (+0.17), CELG: 100.66 (+1.43)
Endocyte Reports Fourth Quarter and Year End 2015 Financial Results and Provides Clinical and Pipeline Update
GlobeNewswire - Wed Mar 02, 3:01PM CST
- EC1456 and EC1169 Advance in Phase 1 Dose Escalation Studies -
ECYT: 3.52 (+0.20)
What's in Store for Endocyte (ECYT) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue Mar 01, 4:19PM CST
Endocyte, Inc. (ECYT) is slated to report fourth-quarter 2015 results on Mar 2, 2016.
ECYT: 3.52 (+0.20), VRX: 22.25 (+0.61), ADRO: 10.93 (+0.70), MRNS: 1.43 (+0.09)
BUYINS.NET: SOXL, AMRC, GDOT, SCHC, ECYT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Feb 04, 6:31AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Direxion Daily Semiconductor Bull 3X Shares (NYSE:SOXL), Ameresco Inc (NYSE:AMRC), Green Dot Corp (NYSE:GDOT), Schwab US Large Cap Etf (NYSE:SCHC), ENDOCYTE INC (NASDAQ:ECYT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
AMRC: 4.97 (+0.16), ECYT: 3.52 (+0.20), GDOT: 22.40 (+0.36), SOXL: 31.52 (+2.28), SCHC: 30.47 (+0.65)
